2014
Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5
Simpson CA, Foer D, Lee GS, Bihuniak J, Sun B, Sullivan R, Belsky J, Insogna KL. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. Osteoporosis International 2014, 25: 2383-2388. PMID: 24927689, PMCID: PMC4659359, DOI: 10.1007/s00198-014-2767-5.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAgedBone DensityBone Morphogenetic ProteinsCase-Control StudiesFemaleGenetic MarkersGenotypeHumansIntercellular Signaling Peptides and ProteinsLow Density Lipoprotein Receptor-Related Protein-5MaleMiddle AgedMutationOsteoprotegerinProto-Oncogene ProteinsRANK LigandSex CharacteristicsWnt Signaling PathwayConceptsFrizzled-related protein 4Serum levelsWnt inhibitorsDickkopf-1Normal controlsUnrelated normal controlsHigh bone mass mutationsHigh bone mass syndromeFunction mutationsNormal age-matched controlsProtein 4Cross-sectional studyAge-matched controlsLRP5 resultSkeletal effectsEndogenous Wnt inhibitorsMass syndromeConsented volunteersUnrelated normal individualsDkk-1Different kindredsNormal individualsLRP5 signalingPatientsSclerostin
2009
Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone*
Williams BO, Insogna KL. Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone*. Journal Of Bone And Mineral Research 2009, 24: 171-178. PMID: 19072724, PMCID: PMC3276354, DOI: 10.1359/jbmr.081235.BooksConceptsEffects of WntWnt pathwayBone metabolismDuodenal enterochromaffin cellsBone anabolic agentAction of WntNoncanonical signaling pathwaysRegulation of sclerostinDownstream effector moleculesEndogenous Wnt inhibitorsBone cell metabolismImportant regulatory moleculesAnabolic actionEnterochromaffin cellsSmall molecule inhibitorsSerotonin synthesisDrug discoveryTrophic stimuliNew therapiesBone anabolismAnabolic agentsTherapeutic targetEndocrine fashionFinal pathwayCentral regulator